Although most vestibular schwannomas (VS) occur sporadically, both sporadic and hereditary tumors share common molecular features beyond the loss of NF2. New evidence highlights the role of interconnected signaling pathways and epigenetic regulation in Schwann cell tumorigenesis, pointing toward potential molecularly targeted therapeutic strategies.
No actionable change at this time — this is a foundational science review; its clinical implications for hearing management in vestibular schwannoma patients remain indirect and long-term.
Understanding the full genetic and epigenetic landscape of vestibular schwannoma beyond NF2 mutations could open new therapeutic targets and refine hearing-preservation strategies for both sporadic and hereditary cases.
- 01Reviews both NF2-dependent and NF2-independent genetic and epigenetic drivers of vestibular schwannoma.
- 02Covers sporadic (random) and hereditary (inherited) forms, highlighting shared molecular features.
- 03Explores the mechanisms linking tumour biology to hearing loss — a key concern for audiologists.
- 04Discusses emerging treatment approaches informed by epigenetic and genetic insights.
- 05Published in Journal of Neuro-Oncology (2026), reflecting growing focus on molecularly stratified care.
Sporadic and hereditary vestibular schwannomas share molecular features beyond NF2 gene loss.
studypartially supportedEpigenetic mechanisms contribute to vestibular schwannoma pathogenesis independently of NF2 mutation.
studypartially supportedEmerging therapies informed by genetic and epigenetic profiling may improve hearing preservation outcomes.
opinionunclear- PMID
- 42143176
- DOI
- 10.1007/s11060-026-05621-4.
- Journal
- Journal of Neuro-Oncology
- Publication type
- review
- Evidence level
- 5
- Population
- Patients with sporadic and hereditary vestibular schwannoma (literature review, no direct patient cohort)
- Intervention
- Genetic and epigenetic profiling and emerging therapies for vestibular schwannoma
Primary outcomes
Genetic and epigenetic mechanisms of vestibular schwannoma formation; Hearing loss mechanisms related to tumour biology; Emerging therapeutic strategies